Bit.bio announces cell therapy pipeline
Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter clinical development in 2025.
The company’s lead cell therapy candidate, bbHEP01, is currently in development as a treatment for patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). The candidate comprises “encapsulated allogeneic induced hepatocyte-like cells (txHepatocytes) produced by bit.bio’s opti-ox precision cell programming technology,” according to the company’s press release.
The drug is intended to provide transient liver function support, in order to allow native liver recovery or provide a path to transplant.
As well as sharing its pipeline, bit.bio has announced changes to its Scientific Advisory Board (SAB), through the appointments of Anil Dhawan MBBS MD FRCPCH, Katy Rezvani MD PhD and Loïc Vincent PhD.
Mark Kotter, founder and chief executive officer of bit.bio, commented: “bit.bio’s mission is to democratise access to cell therapies. Our growing portfolio of therapeutic bit.bio txCells will enable a broad pipeline of regenerative and immune cell therapies, which we will develop either independently or in collaboration with external partners. I’m excited to welcome Drs Katy Rezvani, Anil Dhawan and Loïc Vincent to our SAB. Drawing on the combined expertise of our expanded SAB, we will proceed rapidly and thoughtfully, taking a risk-based approach. We will focus on areas of high unmet medical need where clinical risk has been mitigated by prior clinical studies. Our lead development candidate in acute liver failure exemplifies this approach.”
AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next …
The Japanese health ministry has approved a study testing the use of induced pluripotent stem …